Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
about
Arginine deprivation therapy for malignant melanomaArginine Metabolism in Bacterial Pathogenesis and Cancer TherapyTargeting amino acid metabolism in cancer growth and anti-tumor immune responsePathways and therapeutic targets in melanomaCrystal Structures of Complexes with Cobalt-Reconstituted Human Arginase IExpression of argininosuccinate synthetase in patients with hepatocellular carcinomaAmino acid deprivation using enzymes as a targeted therapy for cancer and viral infectionsOverexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissueMolecular profiling of platinum resistant ovarian cancer.The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signalingProteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation.RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cellsPegylated arginine deiminase: a novel anticancer enzyme agent.Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse modelProteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines.Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetaseHepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency.Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells.Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinomaA phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.Arginine deprivation as a targeted therapy for cancer.TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivationRecombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cellsDisruption of Pseudomonas putida by high pressure homogenization: a comparison of the predictive capacity of three process models for the efficient release of arginine deiminase.
P2860
Q24634269-DF05CA94-C9AE-4430-B23D-E5ACC660C3FCQ26765461-EF94F92D-0CA4-4755-8084-65CB6FF42FC4Q26775425-FADB20DC-6CAF-4BE9-B4FE-903F2EE87531Q26865736-173BBAE8-A1CE-4217-96EE-09A7BF6368EBQ27672035-2AD45724-E63C-48EB-9D09-73CB82E1B3DEQ28283880-66439957-DFE8-4B67-9809-A2A7792F6D86Q30040775-BA14F442-87FB-4F42-8A25-C6148E33724DQ31139529-1E133AA3-5057-46B6-9552-A9A57C66D35FQ33227163-599F9B61-B507-406F-AB2D-FCEEF2CFB464Q33838601-29259ACA-56E1-4736-B372-3404C9A37122Q34213639-51F94BB6-56EB-462D-AAF4-A1AAB4E25F02Q34250146-9C95B41C-E76E-4202-9823-94FF1C72A592Q34305783-43D203A2-94BC-4ED7-8528-681FA1BB67C4Q34609315-FC0D4382-8CEC-4748-9DEC-9293E5DA48EFQ34768395-2AFE2F8A-3D92-439A-A5C0-9F72EC6EEDCDQ34807813-EE00FACF-3773-4382-87BF-EB10A8055670Q34832425-65F7DE15-B9E1-4F17-9FCC-CF979F01F862Q34911774-82ACE25D-36E4-4406-B7F8-3B70A022120EQ35015474-17B4484B-566F-41F8-BD75-82D4AAD51418Q35021230-9ABD51DC-B628-4CDD-BEA0-155D9D10E7C8Q35170154-E411389E-E7C4-48C6-A639-25337DD1C628Q35233239-0C09C316-DE9B-4AA6-89B4-1F5CE8A2A4CDQ35556985-895A5C31-CB62-4E0A-9337-303538A070A7Q35674875-0393CF70-A50B-462C-A78D-3C386DA1310DQ35682009-D62F0945-8FD7-42E4-BF93-CF62853D6330Q35741066-A61435F1-9B34-4A03-A30B-BDA445E2D516Q35927116-73A905F6-5DBF-47BC-A810-1D48199B8A0CQ35957293-FAA88301-B0DC-4CD1-A83F-F4F9A5B323C0Q35959234-F6D64875-2387-43C7-8CC4-59496400AD79Q36106835-D9543FB4-5C23-4B77-A1FD-98146F6B1C6DQ36214996-D12334F2-6EA8-461E-8F4C-628A693428B2Q36277197-2AD119C8-EAAA-4900-BE7E-11DD59B871E0Q36557480-6D4BCF95-477F-4011-89D1-2CB5C7C5F167Q36873800-3DBFFE1A-FD11-4FE4-ABAD-54C1288CB7A0Q37068792-DAF90057-A5FF-4506-B955-ADBF0F96F7A6Q37155873-0A2E6520-37BF-4767-8777-640D2BD38934Q37160927-AB385907-804B-40AC-9B19-1F69BE34DA5DQ37167357-70BFF994-9005-475B-8482-6760F7340D04Q37299640-04D183C5-AB0F-49D6-9E66-3ED5573D5AC9Q37306342-1E719835-DA49-4E84-B644-5AA0B1369A4A
P2860
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Incidence and distribution of ...... itive to arginine deprivation.
@en
Incidence and distribution of ...... itive to arginine deprivation.
@nl
type
label
Incidence and distribution of ...... itive to arginine deprivation.
@en
Incidence and distribution of ...... itive to arginine deprivation.
@nl
prefLabel
Incidence and distribution of ...... itive to arginine deprivation.
@en
Incidence and distribution of ...... itive to arginine deprivation.
@nl
P2093
P2860
P356
P1433
P1476
Incidence and distribution of ...... itive to arginine deprivation.
@en
P2093
Brian J Dillon
C Mark Ensor
Frederick W Holtsberg
John S Bomalaski
Mike A Clark
Steven A Curley
Victor G Prieto
P2860
P304
P356
10.1002/CNCR.20057
P407
P577
2004-02-01T00:00:00Z